NCIt definition : A recombinant humanized immunoglobulin G4 kappa (IgG4k) monoclonal antibody directed
against B- and T-lymphocyte attenuator (BTLA), with potential immunomodulating and
antineoplastic activities. Upon intravenous infusion administration, tifcemalimab
targets and binds to BTLA. This prevents BTLA-mediated inhibition of T-cell activation
leading to antigen specific T-cell proliferation and activation of a cytotoxic T-lymphocyte
(CTL)-mediated immune response against tumor cells. BTLA, an immunoglobulin (Ig) receptor
family member expressed on activated T- and B- lymphocytes, subsets of dendritic cells
(DCs), macrophages, and nature killer (NK) cells, is an immune checkpoint involved
in suppressing immune responses. It mediates inhibition of human tumor-specific CTLs
upon engagement by tumor expressed herpesvirus-entry mediator (HVEM).;
UNII : D40H7X1YZ0;
CAS number : 2236068-83-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2236068-83-8
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Semantic type(s)